Scientific basis for the combination of tegafur with uracil.
Fujii et al reported that Uracil potentiated the antitumor activity of fluorouracil (5-FU) and 1-(2-tetrahydrofuryl)-5-fluorouracil (tegafur). This effect was due to inhibition of the degradation of 5-FU, yet the phosphorylation of 5-FU was unaffected. The molar ratio of tegafur and uracil was 1:4, a combination that has since been widely prescribed in Japan for the treatment of cancer patients. We present here our experimental and clinical results when investigating the antineoplastic effects of this combination of drugs--known as UFT--and provide evidence that UFT is an effective treatment for patients with cancer.
Maehara
Y
Y
Department of Surgery II, Faculty of Medicine, Kyushu University, Fukuoka, Japan.
Kakeji
Y
Y
Ohno
S
S
Baba
H
H
Sugimachi
K
K
D017024:Chemotherapy, Adjuvant; D004305:Dose-Response Relationship, Drug; D004338:Drug Combinations; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000097:blood; D005743:Gastrectomy / Q000009:adverse effects; D006801:Humans; D007408:Intestinal Absorption; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage; D011182:Postoperative Care; D013274:Stomach Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000401:mortality; D016019:Survival Analysis; D005641:Tegafur / Q000737:chemistry / Q000378:metabolism / Q000627:therapeutic use*; D014498:Uracil / Q000737:chemistry / Q000378:metabolism / Q000627:therapeutic use*
D004338:Drug Combinations; C096910:UFT(R) drug; D005641:Tegafur; D016685:Mitomycin; D014498:Uracil; D005472:Fluorouracil